Benjamin Tomlinson
Hematology & Oncology · Cleveland, OHNPI 1083841092
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,076 of the $10,683 with a category attached, or 66.2%. Bristol Myers Squibb accounts for 82.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $6,500 and has fallen 89.7% since, to $667 in 2025.
Across 78 payments — averaging $136.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$9K
- Pfizer$302
- Daiichi Sankyo Inc.$270
- Novartis$169
- Janssen Research & Development, LLC$146
- Seagen Inc.$141
- plus $881 from 25 others
Across 111 payments — averaging $14,324 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$983K
- AbbVie$187K
- Seagen Inc.$166K
- Bristol Myers Squibb$99K
- Astellas Pharma Global Development$74K
- Janssen Research & Development, LLC$42K
- plus $39K from 3 others
What the payments were for
- Consulting fees$7,07666%
- Speaking & faculty fees$1,50014%
- Food & beverage$2,10620%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 8 | $8,774 |
| Pfizer | 10 | $302 |
| Daiichi Sankyo Inc. | 6 | $270 |
| Novartis | 10 | $169 |
| Janssen Research & Development, LLC | 1 | $146 |
| Seagen Inc. | 2 | $141 |
| Sanofi | 4 | $94 |
| Merck | 4 | $87 |
| Incyte Corporation | 3 | $77 |
| Beone Medicines USA, Inc. | 2 | $65 |
| Astellas Pharma US Inc | 2 | $56 |
| Agios Pharmaceuticals, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| AstraZeneca(2 entities) | 3 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| AbbVie | 2 | $39 |
| Genentech USA, Inc. | 1 | $32 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $20 |
| GSK | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Morphosys, US Inc. | 1 | $17 |
| Epizyme, Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,683 in reported general payments places this provider in the 70th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 93 | $530,507 |
| PromactaEltrombopag Olamine | 17 | $484,375 |
| TibsovoIvosidenib | 14 | $418,013 |
| ScemblixAsciminib Hydrochloride | 19 | $408,905 |
| BrukinsaZanubrutinib | 24 | $362,066 |
| RevlimidLenalidomide | 15 | $319,381 |
| JakafiRuxolitinib Phosphate | 27 | $306,980 |
| ImbruvicaIbrutinib | 11 | $240,170 |
| EliquisApixaban | 16 | $14,894 |
| Ondansetron Hcl | 65 | $6,132 |
| Fluconazole | 52 | $2,142 |
| Danazol | 11 | $1,778 |
| Acyclovir | 82 | $1,132 |
| Prochlorperazine Maleate | 55 | $634 |
| Hydroxyurea | 20 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Scemblix | $169 | $893,28036 claims |
| AbbVieVenclexta | $39 | $530,50793 claims |
| Bristol Myers SquibbRevlimid | $8,774 | $319,38115 claims |
| Incyte CorporationJakafi | $77 | $306,98027 claims |
| PfizerEliquis | $302 | $14,89416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.